ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer

Zhou Qing; Zhang Xu Chao; Chen Zhi Hong; Yin Xiao Lu; Yang Jin Ji; Xu Chong Rui; Yan Hong Hong; Chen Hua Jun; Su Jian; Zhong Wen Zhao; Yang Xue Ning; An She Juan; Wang Bin Chao; Huang Yi Sheng; Wang Zhen; Wu Yi Long*广东省人民医院
Journal of Clinical Oncology2011-8-20DOI: 10.1200/JCO.2010.33.3757
80被引9阅读
引用收藏
分享

摘要

Purpose Our aim was to determine whether abundance of epidermal growth factor receptor (EGFR) mutations in tumors predicts benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs) for advanced non-small-cell lung cancer (NSCLC). <br>Patients and Methods We detected EGFR mutations in 100 lung cancer samples using direct DNA sequencing and amplification refractory mutation system (ARMS). Mutation-positive tumors by both methods carried high abundance of EGFR mutations. Tumors that were mutation positive by ARMS but mutation negative by direct DNA sequencing harbored low abundance of EGFR mutations. Mutation-negative tumors by both methods carried wild-type EGFR. All patients received gefitinib treatment. The correlation between EGFR mutation abundance and clinical benefit from gefitinib treatment was analyzed. <br>Results Of 100 samples, 51 and 18 harbored high and low abundances of EGFR mutations, respectively; 31 carried wild-type EGFR. Median progression-free survival (PFS) was 11.3 (95% CI, 7.4 to 15.2) and 6.9 months (95% CI, 5.5 to 8.4) in patients with high and low abundances of EGFR mutations, respectively (P = .014). Median PFS of patients with low abundance of EGFR mutations was significantly longer than that of those with wild-type tumors (2.1 months; 95% CI, 1.0 to 3.2; P = .010). Objective response rates (ORRs) were 62.7%, 44.4%, and 16.1%, and overall survival (OS) rates were 15.9 (95% CI, 13.4 to 18.3), 10.9 (95% CI, 2.7 to 19.1), and 8.7 months (95% CI, 4.6 to 12.7) for patients with high abundance of EGFR mutations, low abundance of EGFR mutations, and wild-type EGFR, respectively. The difference between patients with high and low abundances of EGFR mutations was not significant regarding ORR and OS. <br>Conclusion The relative EGFR mutation abundance could predict benefit from EGFR-TKI treatment for advanced NSCLC. J Clin Oncol 29: 3328-3330.

相关
加载中…
  • Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng; Liang, Li; Hu, Yi; Huang, Cheng; Zhou, Caicun; Shi, Yuankai; Zhang, Li; Ye, Xin; Zhang, Meizhuo; Chuai, Shaokun; Zhu, Guanshan; Hu, Jin; Wu, Yi-Long*; Wang, Jie*Lancet Respir Med, 2018, 6(9): 681-690.
  • Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial
    Li, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*Clinical Lung Cancer, 2021, 22(2): 100-+.被引 28
  • &Delta;CT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study
    Chen, Min; Huang, Wenqi; Yang, Dongyong; Huang, Jincheng; Li, Gong; Wang, Xiaoqing; Xiao, Nanjie; Zhang, Weijian; Guan, Jian*; Wang, Shuang*; Liu, Laiyu*Frontiers in Molecular Biosciences, 2021, 8: 684661.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical Oncology
发表日期
2011-08-20
卷期
第 29 卷, 第 24 期
页码
3316-3321
DOI
10.1200/JCO.2010.33.3757
语言
ENGLISH
成果收录
SCI
资助标注
National Natural Science Foundation of China [30772531]; Guangdong Science and Technology Department [2007A032000002, 2006B60101010]; National "863" Division of Keystone Project [2006AA02A401]

作者

  • Z

    Zhou Qing (第一作者)

    guangdong gen hosp

  • Z

    Zhang Xu Chao

    guangdong gen hosp

查看全部 16 位作者收起作者
  • C

    Chen Zhi Hong

    guangdong gen hosp

  • Y

    Yin Xiao Lu

  • Y

    Yang Jin Ji

    guangdong gen hosp

  • X

    Xu Chong Rui

    guangdong gen hosp

  • Y

    Yan Hong Hong

    guangdong gen hosp

  • C

    Chen Hua Jun

    guangdong gen hosp

  • S

    Su Jian

    guangdong gen hosp

  • Z

    Zhong Wen Zhao

    guangdong gen hosp

  • Y

    Yang Xue Ning

    guangdong gen hosp

  • A

    An She Juan

    guangdong gen hosp

  • W

    Wang Bin Chao

    guangdong gen hosp

  • H

    Huang Yi Sheng

    guangdong gen hosp

  • W

    Wang Zhen

    guangdong gen hosp

  • W

    Wu Yi Long (通讯)

    guangdong gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417